Literature DB >> 11310155

On prognostic models, artificial intelligence and censored observations.

S S Anand1, P W Hamilton, J G Hughes, D A Bell.   

Abstract

The development of prognostic models for assisting medical practitioners with decision making is not a trivial task. Models need to possess a number of desirable characteristics and few, if any, current modelling approaches based on statistical or artificial intelligence can produce models that display all these characteristics. The inability of modelling techniques to provide truly useful models has led to interest in these models being purely academic in nature. This in turn has resulted in only a very small percentage of models that have been developed being deployed in practice. On the other hand, new modelling paradigms are being proposed continuously within the machine learning and statistical community and claims, often based on inadequate evaluation, being made on their superiority over traditional modelling methods. We believe that for new modelling approaches to deliver true net benefits over traditional techniques, an evaluation centric approach to their development is essential. In this paper we present such an evaluation centric approach to developing extensions to the basic k-nearest neighbour (k-NN) paradigm. We use standard statistical techniques to enhance the distance metric used and a framework based on evidence theory to obtain a prediction for the target example from the outcome of the retrieved exemplars. We refer to this new k-NN algorithm as Censored k-NN (Ck-NN). This reflects the enhancements made to k-NN that are aimed at providing a means for handling censored observations within k-NN.

Entities:  

Mesh:

Year:  2001        PMID: 11310155

Source DB:  PubMed          Journal:  Methods Inf Med        ISSN: 0026-1270            Impact factor:   2.176


  1 in total

Review 1.  Artificial neural networks for predictive modeling in prostate cancer.

Authors:  Eduard J Gamito; E David Crawford
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.075

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.